DrugPatentWatch Database Updates: New Patent Additions
✉ Email this page to a colleague
DrugPatentWatch Database Updates: New Patent Additions
Applicant | Tradename | Generic Name | Dosage | NDA | Number | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist Requested | Patent Expiration | Date Submitted | Usecode | Patented / Exclusive Use |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Janssen Biotech | BALVERSA | erdafitinib | TABLET | 212018 | 001 | Apr 12, 2019 | RX | Yes | ⤷ Try a Trial | Y | ⤷ Try a Trial | 2021-02-19 | U-2518 | TREATMENT OF ADULTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA THAT HAS SUSCEPTIBLE FGFR3 OR FGFR2 GENETIC ALTERATIONS AND PROGRESSED DURING OR FOLLOWING PRIOR PLATINUM-CONTAINING CHEMOTHERAPY | ||
Janssen Biotech | BALVERSA | erdafitinib | TABLET | 212018 | 002 | Apr 12, 2019 | RX | Yes | ⤷ Try a Trial | Y | ⤷ Try a Trial | 2021-02-19 | U-2518 | TREATMENT OF ADULTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA THAT HAS SUSCEPTIBLE FGFR3 OR FGFR2 GENETIC ALTERATIONS AND PROGRESSED DURING OR FOLLOWING PRIOR PLATINUM-CONTAINING CHEMOTHERAPY | ||
Janssen Biotech | BALVERSA | erdafitinib | TABLET | 212018 | 003 | Apr 12, 2019 | RX | Yes | ⤷ Try a Trial | Y | ⤷ Try a Trial | 2021-02-19 | U-2518 | TREATMENT OF ADULTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA THAT HAS SUSCEPTIBLE FGFR3 OR FGFR2 GENETIC ALTERATIONS AND PROGRESSED DURING OR FOLLOWING PRIOR PLATINUM-CONTAINING CHEMOTHERAPY | ||
Janssen Biotech | BALVERSA | erdafitinib | TABLET | 212018 | 001 | Apr 12, 2019 | RX | Yes | ⤷ Try a Trial | Y | ⤷ Try a Trial | 2021-02-19 | U-3065 | TREATMENT OF ADULTS WITH METASTATIC UROTHELIAL CARCINOMA THAT HAS SUSCEPTIBLE FGFR3 OR FGFR2 GENETIC ALTERATIONS AND PROGRESSED DURING OR FOLLOWING PRIOR PLATINUM-CONTAINING CHEMOTHERAPY | ||
Janssen Biotech | BALVERSA | erdafitinib | TABLET | 212018 | 002 | Apr 12, 2019 | RX | Yes | ⤷ Try a Trial | Y | ⤷ Try a Trial | 2021-02-19 | U-3065 | TREATMENT OF ADULTS WITH METASTATIC UROTHELIAL CARCINOMA THAT HAS SUSCEPTIBLE FGFR3 OR FGFR2 GENETIC ALTERATIONS AND PROGRESSED DURING OR FOLLOWING PRIOR PLATINUM-CONTAINING CHEMOTHERAPY | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Number | >Approval Date | >Type | >RLD | >Patent No. | >Product | >Substance | >Delist Requested | >Patent Expiration | >Date Submitted | >Usecode | >Patented / Exclusive Use |